Super-enhancers are a specialized class of functional, non-coding RNA molecules transcribed directly from regions of the ...
The FDA granted Fast Track designation to HTX-001, an investigational lncRNA-targeting antisense therapy for nonobstructive hypertrophic cardiomyopathy.
Design Therapeutics' DT-216P2 showed 6.4-point mFARS gains in Friedreich’s ataxia, but data is early. Click here to read the ...
Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy in development for Angelman syndrome, advanced into the pivotal ...
Morning Overview on MSN
A new Alzheimer’s blood marker may reveal when symptoms are close
Researchers have identified a set of 34 circular RNAs in blood that can detect Alzheimer’s disease with striking accuracy and ...
HAYA Therapeutics has announced full enrolment and dosing of the first cohort in its Phase I clinical trial of HTX-001, a long non-coding ribonucleic acid (lncRNA)-targeting therapy developed for ...
Transaction to provide Oak Hill Bio with approximately $175 million in gross proceeds, including $75 million of cash in Research Alliance ...
Transaction to provide Oak Hill Bio with approximately $175 million in gross proceeds, including $75 million of cash in Research Alliance Corporation III’s (Nasdaq: RACC) (“RA ...
Spread the loveIt’s no secret that anxiety is a pervasive issue, touching countless lives. You might have tried everything ...
Spread the love“`html For years, mental health discussions largely focused on the brain – neurotransmitters, psychology, and ...
All cells in the human body—and the motions they enable, from our beating hearts to our wiggling toes—use energy generated by ...
A single IV injection of a microRNA-based biologic developed by Guangping Gao, Ph.D., Robert H. Brown Jr., DPhil, MD, Jun Xie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results